GEN - Genetic Engineering and Biotechnology News17 小时
In Vivo Base Editing Gets Boost with Positive Initial Data Announced by Beam Therapeutics
Beam Therapeutics announced positive initial data for BEAM-302 in the Phase I/II trial in Alpha-1 Antitrypsin Deficiency (AATD).
Zacks Investment Research on MSN16 小时
BEAM Down Despite Positive Initial Data From Genetic Disorder Study
Beam Therapeutics Inc. BEAM announced positive initial safety and efficacy data from a phase I/II study, which is evaluating ...